Lantern Pharma publishes investor presentation on AI-driven oncology drug development platform, pipeline programs

Lantern Pharma, Inc.

Lantern Pharma, Inc.

LTRN

0.00
  • Lantern Pharma highlighted its RADR AI platform, targeting a 70% cut in early-stage development timelines and an 80% reduction in costs.
  • RADR was cited as predicting and stratifying real-world trial patients with 88% accuracy, supporting biomarker-driven enrollment strategies.
  • Lead program LP-300 is in a Phase 2 trial in never-smoker NSCLC, with preliminary data showing an 86% clinical benefit rate.
  • LP-300 showed a median progression-free survival of 8.4 months in an EGFR exon 21 L858R cohort; disease control rate was 87%.
  • Pipeline update included LP-284 in Phase 1 for recurrent lymphomas and soft tissue sarcomas; LP-184 advanced solid-tumor trials planned.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on July 10, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.